TFFP TFF Pharmaceuticals
- 1.9500
- +0.0200+1.04%
TFF Pharmaceuticals News
Express News | TFF Pharmaceuticals Inc - Mcm Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated in Vitro and Ex Vivo Models
Express News | TFF Pharmaceuticals Inc - Co and Leidos to Advance Next-Generation Biodefense Countermeasures Under Darpa PPB Program Into Preclinical Testing
Express News | TFF Pharmaceuticals, Cleveland Clinic Partner To Advance Multiple Multivalent Universal Influenza Vaccines To Protect Against Seasonal, Pandemic Viruses Into Preclinical Testing
Express News | TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates Into Preclinical Testing
Express News | TFF Pharmaceuticals : Entered Into an at Market Offering Agreement With H.c. Wainwright & Co., LLC
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersScorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KT
Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential
Express News | TFF Pharmaceuticals Inc : Jonestrading Cuts Target Price to $4 From $13
Express News | TFF Pharmaceuticals Inc: Anticipate Providing a More Detailed Clinical Update on Phase 2 Trial Later in Year
Express News | TFF Pharmaceuticals Inc: Variability in Systemic Exposure to Tacrolimus Was Reduced With TFF Tac
Express News | TFF Pharmaceuticals Enrolls 10 Patients in Phase 2 Trial
Express News | TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Express News | TFF Pharmaceuticals Expects To Receive FDA Feedback In Q2 Regarding TFF TAC Clinical Development Plan And Next Steps
Express News | TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate
Express News | TFF Pharmaceuticals Inc: Expects to Receive Feedback From FDA in Q2 Regarding TFF Tac Clinical Development Plan and Next Steps
TFF Pharmaceuticals | 10-Q: Quarterly report
Express News | TFF Pharmaceuticals Q1 Basic EPS USD -2.4
Express News | TFF Pharmaceuticals Q1 Net Income USD -5.7 Million
Press Release: TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC)
TFF Pharmaceuticals 1Q Loss/Shr $2.40 >TFFP
TFF Pharmaceuticals 1Q Loss/Shr $2.40 >TFFP
Analysis
Price Target
No Data
